CD274 and cervical carcinoma: Specifically, monoclonal antibodies (mAbs) have been developed to enhance the innate NK cell response against cervical cancer cells, including the anti-PD-1 mAbs nivolumab and pembrolizumab and the anti-PD-L1/2 mAbs MPDL3280A and AMP-224 (8, 9).